Long-term safety of adalimumab in clinical trials in adult patients with Crohn's disease or ulcerative colitis.
Fiche publication
Date publication
janvier 2018
Journal
Alimentary pharmacology & therapeutics
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
Colombel JF, Sandborn WJ, Reinisch W, Peyrin-Biroulet L, Panaccione R, Rutgeerts P, Hanauer SB, Ghosh S, Van Assche G, Robinson AM, Lau W, Maa JF, Huang B, Pappalardo B, Read H
Lien Pubmed
Résumé
Adalimumab is used to treat moderate to severe Crohn's disease (CD) and ulcerative colitis (UC) when conventional therapies fail.
Mots clés
Adalimumab, administration & dosage, Adolescent, Adult, Aged, Clinical Trials as Topic, statistics & numerical data, Colitis, Ulcerative, drug therapy, Crohn Disease, drug therapy, Drug-Related Side Effects and Adverse Reactions, epidemiology, Female, Humans, Long-Term Care, Male, Middle Aged, Opportunistic Infections, chemically induced, Time Factors, Young Adult
Référence
Aliment. Pharmacol. Ther.. 2018 01;47(2):219-228